Document is current
Any future updates will be listed below
-
Authors
Lledó-Delgado, Ana
Preston-Hurlburt, Paula
Higdon, Lauren
Hu, Alex
James, Eddie https://orcid.org/0000-0002-7217-5729
Lim, Noha
Long, S. Alice https://orcid.org/0000-0002-0281-1240
McNamara, James
Nguyen, Hai
Serti, Elisavet https://orcid.org/0000-0003-4129-0254
Sumida, Tomokazu S. https://orcid.org/0000-0002-9806-2642
Herold, Kevan C. https://orcid.org/0000-0003-1534-6613
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | Office of Extramural Research, National Institutes of Health (DK057846, AI66387, UM1AI109565)
Colton Foundation
- License Information
-
More Information
Article History
Received: 13 June 2023
Accepted: 20 May 2025
First Online: 30 May 2025
Competing interests
: S.A.L. and K.C.H. are listed as a co-inventors for a patent on the use of teplizumab for delay of Type 1 diabetes. K.C.H. has consulted for Sanofi Pharma. The other authors declare no competing interests
